Literature DB >> 32869188

Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.

Baicheng Li1, Xinjun Li2, Ruiqi Mao1, Min Liu3, Limei Fu1, Lifang Shi1, Songlin Zhao1, Mingxia Fu1.   

Abstract

Gastrointestinal tract neuroendocrine neoplasms (NENs) are a group of rare heterogeneous tumors with different prognoses. The 2019 WHO classification of digestive system tumors defines the classification of NENs as neuroendocrine tumors (NETs G1-G3) and neuroendocrine carcinomas (NECs). We investigated outer dense fiber of sperm tails 1 (ODF1) expression in 137 gastrointestinal tract NENs including 53 NETs G1, 29 NETs G2, 3 NETs G3, and 52 NECs. Twenty adenocarcinomas and 6 squamous cell carcinomas also were included in the study. The results showed that ODF1 was positive in 83 of 85 (97.6%) primary gastrointestinal tract NETs, including 9 of 10 (90%) gastric, 19 of 19 (100%) small bowel, 10 of 11 (90.9%) colorectal, and 45 of 45 (100%) appendiceal neoplasms. There was a significantly statistical difference in the rates of ODF1 positivity in NETs (83/85, 97.6%) vs NECs (25/52, 48.1%, P < 0.001). ODF1 showed diffuse staining in NETs G1 (53/53, 100%) and NETs G2 (28/29, 96.6%), > 50% staining in NETs G3 (2/3, 66.7%), and focal staining (< 50%) in NECs (23/52, 44.2%) but 2 cases (2/52) showed > 50% staining. ODF1 showed no expression in all 20 adenocarcinomas and 6 squamous cell carcinomas. In conclusion, ODF1 was firstly identified as a novel marker for NENs, especially for NETs in the gastrointestinal tract. The expression mechanism and clinical significance of ODF1 in NENs needed further study.

Entities:  

Keywords:  Gastrointestinal tract; Immunohistochemistry; Neuroendocrine neoplasms; ODF1

Year:  2020        PMID: 32869188     DOI: 10.1007/s12022-020-09649-8

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  13 in total

1.  Synaptic vesicle protein 2, A new neuroendocrine cell marker.

Authors:  G M Portela-Gomes; A Lukinius; L Grimelius
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

Authors:  Halfdan Sorbye; Eric Baudin; Aurel Perren
Journal:  Endocrinol Metab Clin North Am       Date:  2018-07-11       Impact factor: 4.741

3.  Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.

Authors:  Hee Sung Kim; Hye Seung Lee; Kyung Han Nam; Jiwoon Choi; Woo Ho Kim
Journal:  Anticancer Res       Date:  2015-06       Impact factor: 2.480

4.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

5.  Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.

Authors:  Björn Konukiewitz; Anna Melissa Schlitter; Moritz Jesinghaus; Dominik Pfister; Katja Steiger; Angela Segler; Abbas Agaimy; Bence Sipos; Giuseppe Zamboni; Wilko Weichert; Irene Esposito; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 6.  Outer Dense Fiber Proteins: Bridging between Male Infertility and Cancer.

Authors:  Faezeh Azizi; Soudeh Ghafouri-Fard
Journal:  Arch Iran Med       Date:  2017-05       Impact factor: 1.354

7.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

8.  A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

Authors:  Laura H Tang; Olca Basturk; Jillian J Sue; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

9.  DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.

Authors:  Joo Kyung Park; Woo Hyun Paik; Kyoungbun Lee; Ji Kon Ryu; Sang Hyub Lee; Yong-Tae Kim
Journal:  Oncotarget       Date:  2017-07-25

10.  Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer.

Authors:  Kimberly E Maxfield; Patrick J Taus; Kathleen Corcoran; Joshua Wooten; Jennifer Macion; Yunyun Zhou; Mark Borromeo; Rahul K Kollipara; Jingsheng Yan; Yang Xie; Xian-Jin Xie; Angelique W Whitehurst
Journal:  Nat Commun       Date:  2015-11-16       Impact factor: 14.919

View more
  4 in total

Review 1.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

Review 2.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Authors:  Ozgur Mete; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2022-03-21

3.  Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.

Authors:  Ranran Shi; Xiuman Zhou; Liwei Pang; Mingshuang Wang; Yubing Li; Chunxia Chen; Haoming Ning; Lihan Zhang; Guangxing Yue; Lu Qiu; Wenshan Zhao; Yuanming Qi; Yahong Wu; Yanfeng Gao
Journal:  Cancer Immunol Immunother       Date:  2022-10-17       Impact factor: 6.630

Review 4.  Insights on Human Small Heat Shock Proteins and Their Alterations in Diseases.

Authors:  B Tedesco; R Cristofani; V Ferrari; M Cozzi; P Rusmini; E Casarotto; M Chierichetti; F Mina; M Galbiati; M Piccolella; V Crippa; A Poletti
Journal:  Front Mol Biosci       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.